Lantheus Holdings, Inc. (LNTH): Operating Cash Flow
$390.14M
Year ended 2025-12-31
$412.80M
Trailing 12 months to 2026-06-30
+11.5%
3-year compound annual growth
+88.5%
5-year compound annual growth
+33.5%
10-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $390.14M | -28.4% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $544.75M | +78.5% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $305.26M | +8.3% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $281.78M | +422.6% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $53.92M | +228.8% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $16.40M | -79.6% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $80.38M | +31.4% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $61.19M | +11.7% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $54.78M | +10.3% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $49.64M | +128.1% | 2019-02-20, From 2016-01-01 |
| 2015-12-31 | $21.76M | +87.8% | 2018-02-26, From 2015-01-01 |
| 2014-12-31 | $11.59M | n/m | 2017-02-23, From 2014-01-01 |
| 2013-12-31 | -$15.57M | n/a | 2016-03-02, From 2013-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $390.14M | -28.4% |
| QuidelOrtho Corp (QDEL) | 2025-12-28 | $105.20M | +26.7% |
| Neogen Corp (NEOG) | 2026-05-31 | $83.20M | +43.0% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $1.80M | n/m |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $1.18B | +27.2% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | -$394.74M | n/m |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | -$8.65M | n/m |
| Immucell Corp (ICCC) | 2025-12-31 | $2.48M | +591.6% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | -$7.03M | n/m |
Compare LNTH, QDEL, NEOG, MYGN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗